Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010 | Breast Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Siegel  R, Ma  J, Zou  Z, Jemal  A.  Cancer statistics, 2014.  CA Cancer J Clin. 2014;64(1):9-29.PubMedGoogle ScholarCrossref
2.
Jemal  A, Bray  F, Center  MM, Ferlay  J, Ward  E, Forman  D.  Global cancer statistics.  CA Cancer J Clin. 2011;61(2):69-90.PubMedGoogle ScholarCrossref
3.
Herbst  RS, Bajorin  DF, Bleiberg  H,  et al; American Society of Clinical Oncology.  Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening: a report from the American Society of Clinical Oncology.  J Clin Oncol. 2006;24(1):190-205.PubMedGoogle ScholarCrossref
4.
Griggs  JJ, Culakova  E, Sorbero  ME,  et al.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.  J Clin Oncol. 2007;25(18):2522-2527.PubMedGoogle ScholarCrossref
5.
Gralow  J, Ozols  RF, Bajorin  DF,  et al; American Society of Clinical Oncology.  Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening: a report from the American Society of Clinical Oncology.  J Clin Oncol. 2008;26(2):313-325.PubMedGoogle ScholarCrossref
6.
Edwards  BK, Brown  ML, Wingo  PA,  et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.  J Natl Cancer Inst. 2005;97(19):1407-1427.PubMedGoogle ScholarCrossref
7.
Jemal  A, Clegg  LX, Ward  E,  et al.  Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.  Cancer. 2004;101(1):3-27.PubMedGoogle ScholarCrossref
8.
Siegel  R, Ward  E, Brawley  O, Jemal  A.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.  CA Cancer J Clin. 2011;61(4):212-236.PubMedGoogle ScholarCrossref
9.
Siegel  R, Desantis  C, Jemal  A.  Colorectal cancer statistics, 2014.  CA Cancer J Clin. 2014;64(2):104-117.PubMedGoogle ScholarCrossref
10.
Smith  BD, Jiang  J, McLaughlin  SS,  et al.  Improvement in breast cancer outcomes over time: are older women missing out?  J Clin Oncol. 2011;29(35):4647-4653.PubMedGoogle ScholarCrossref
11.
Robbins  AS, Siegel  RL, Jemal  A.  Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008.  J Clin Oncol. 2012;30(4):401-405.PubMedGoogle ScholarCrossref
12.
Cook  MB, McGlynn  KA, Devesa  SS, Freedman  ND, Anderson  WF.  Sex disparities in cancer mortality and survival.  Cancer Epidemiol Biomarkers Prev. 2011;20(8):1629-1637.PubMedGoogle ScholarCrossref
13.
Jemal  A, Simard  EP, Dorell  C,  et al.  Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels.  J Natl Cancer Inst. 2013;105(3):175-201.PubMedGoogle ScholarCrossref
14.
Hershman  DL, Unger  JM, Barlow  WE,  et al.  Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.  J Clin Oncol. 2009;27(13):2157-2162.PubMedGoogle ScholarCrossref
15.
Freedman  RA, He  Y, Winer  EP, Keating  NL.  Trends in racial and age disparities in definitive local therapy of early-stage breast cancer.  J Clin Oncol. 2009;27(5):713-719.PubMedGoogle ScholarCrossref
16.
Gross  CP, Smith  BD, Wolf  E, Andersen  M.  Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?  Cancer. 2008;112(4):900-908.PubMedGoogle ScholarCrossref
17.
van de Water  W, Markopoulos  C, van de Velde  CJ,  et al.  Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.  JAMA. 2012;307(6):590-597.PubMedGoogle ScholarCrossref
18.
Harper  S, Lynch  J, Meersman  SC, Breen  N, Davis  WW, Reichman  MC.  Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005).  Cancer Epidemiol Biomarkers Prev. 2009;18(1):121-131.PubMedGoogle ScholarCrossref
19.
Castleberry  AW, Güller  U, Tarantino  I,  et al.  Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis.  J Gastrointest Surg. 2014;18(6):1194-1204.PubMedGoogle ScholarCrossref
20.
Jafari  MD, Jafari  F, Halabi  WJ,  et al.  Colorectal cancer resections in the aging US population: a trend toward decreasing rates and improved outcomes [published online April 9, 2014].  JAMA Surg. doi:10.1001/jamasurg.2013.4930.PubMedGoogle Scholar
21.
Ma  J, Siegel  R, Jemal  A.  Pancreatic cancer death rates by race among US men and women, 1970-2009.  J Natl Cancer Inst. 2013;105(22):1694-1700.PubMedGoogle ScholarCrossref
22.
Shao  YH, Demissie  K, Shih  W,  et al.  Contemporary risk profile of prostate cancer in the United States.  J Natl Cancer Inst. 2009;101(18):1280-1283.PubMedGoogle ScholarCrossref
23.
Tannenbaum  SL, Koru-Sengul  T, Zhao  W, Miao  F, Byrne  MM.  Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status.  Cancer J. 2014;20(4):237-245.PubMedGoogle ScholarCrossref
24.
 SEER Research Data 1973-2010—ASCII Text Data. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2013. http://www.seer.cancer.gov. Accessed January 1, 2014.
25.
World Health Organization.  International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
26.
Siegel  R, Naishadham  D, Jemal  A.  Cancer statistics, 2013.  CA Cancer J Clin. 2013;63(1):11-30.PubMedGoogle ScholarCrossref
27.
Howlader  N, Ries  LA, Mariotto  AB, Reichman  ME, Ruhl  J, Cronin  KA.  Improved estimates of cancer-specific survival rates from population-based data.  J Natl Cancer Inst. 2010;102(20):1584-1598.PubMedGoogle ScholarCrossref
28.
Gill  S, Loprinzi  CL, Sargent  DJ,  et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?  J Clin Oncol. 2004;22(10):1797-1806.PubMedGoogle ScholarCrossref
29.
Clarke  M.  Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview.  Ann Oncol. 2006;17(suppl 10):x59-x62.PubMedGoogle ScholarCrossref
30.
El-Serag  HB.  Hepatocellular carcinoma.  N Engl J Med. 2011;365(12):1118-1127.PubMedGoogle ScholarCrossref
31.
Shayne  M, Culakova  E, Poniewierski  MS,  et al.  Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.  Cancer. 2007;110(7):1611-1620.PubMedGoogle ScholarCrossref
32.
Muss  HB, Berry  DA, Cirrincione  C,  et al; Cancer and Leukemia Group B Experience.  Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.  J Clin Oncol. 2007;25(24):3699-3704.PubMedGoogle ScholarCrossref
33.
Hurria  A, Fleming  MT, Baker  SD,  et al.  Pharmacokinetics and toxicity of weekly docetaxel in older patients.  Clin Cancer Res. 2006;12(20, pt 1):6100-6105.PubMedGoogle ScholarCrossref
34.
Caillet  P, Canoui-Poitrine  F, Vouriot  J,  et al.  Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study.  J Clin Oncol. 2011;29(27):3636-3642.PubMedGoogle ScholarCrossref
35.
Lee  L, Cheung  WY, Atkinson  E, Krzyzanowska  MK.  Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.  J Clin Oncol. 2011;29(1):106-117.PubMedGoogle ScholarCrossref
36.
Foster  JA, Salinas  GD, Mansell  D, Williamson  JC, Casebeer  LL.  How does older age influence oncologists’ cancer management?  Oncologist. 2010;15(6):584-592.PubMedGoogle ScholarCrossref
37.
Talarico  L, Chen  G, Pazdur  R.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.  J Clin Oncol. 2004;22(22):4626-4631.PubMedGoogle ScholarCrossref
38.
Murthy  VH, Krumholz  HM, Gross  CP.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.  JAMA. 2004;291(22):2720-2726.PubMedGoogle ScholarCrossref
39.
Lewis  JH, Kilgore  ML, Goldman  DP,  et al.  Participation of patients 65 years of age or older in cancer clinical trials.  J Clin Oncol. 2003;21(7):1383-1389.PubMedGoogle ScholarCrossref
40.
Owusu  C, Buist  DS, Field  TS,  et al.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.  J Clin Oncol. 2008;26(4):549-555.PubMedGoogle ScholarCrossref
41.
Edwards  BK, Howe  HL, Ries  LA,  et al.  Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.  Cancer. 2002;94(10):2766-2792.PubMedGoogle ScholarCrossref
42.
Barnholtz-Sloan  JS, Schwartz  AG, Qureshi  F, Jacques  S, Malone  J, Munkarah  AR.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.  Am J Obstet Gynecol. 2003;189(4):1120-1127.PubMedGoogle ScholarCrossref
43.
Bristow  RE, Powell  MA, Al-Hammadi  N,  et al.  Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.  J Natl Cancer Inst. 2013;105(11):823-832.PubMedGoogle ScholarCrossref
44.
Aranda  MA, McGory  M, Sekeris  E, Maggard  M, Ko  C, Zingmond  DS.  Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer?  Gynecol Oncol. 2008;111(2):166-172.PubMedGoogle ScholarCrossref
45.
DeLancey  JO, Thun  MJ, Jemal  A, Ward  EM.  Recent trends in black-white disparities in cancer mortality.  Cancer Epidemiol Biomarkers Prev. 2008;17(11):2908-2912.PubMedGoogle ScholarCrossref
46.
DeSantis  C, Naishadham  D, Jemal  A.  Cancer statistics for African Americans, 2013.  CA Cancer J Clin. 2013;63(3):151-166.PubMedGoogle ScholarCrossref
47.
Taylor  KL, Davis  JL  III, Turner  RO,  et al.  Educating African American men about the prostate cancer screening dilemma: a randomized intervention.  Cancer Epidemiol Biomarkers Prev. 2006;15(11):2179-2188.PubMedGoogle ScholarCrossref
48.
Najari  BB, Rink  M, Li  PS,  et al.  Sex disparities in cancer mortality: the risks of being a man in the United States.  J Urol. 2013;189(4):1470-1474.PubMedGoogle ScholarCrossref
49.
Zak  Y, Rhoads  KF, Visser  BC.  Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type.  Arch Surg. 2011;146(7):778-784.PubMedGoogle ScholarCrossref
50.
Sonnenday  CJ, Dimick  JB, Schulick  RD, Choti  MA.  Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma.  J Gastrointest Surg. 2007;11(12):1636-1646.PubMedGoogle ScholarCrossref
51.
Wong  RJ, Corley  DA.  Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.  Dig Dis Sci. 2009;54(9):2031-2039.PubMedGoogle ScholarCrossref
52.
Swan  J, Breen  N, Coates  RJ, Rimer  BK, Lee  NC.  Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey.  Cancer. 2003;97(6):1528-1540.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Disparities in the Improvement of Survival for Major Cancers
    Kailin Yang, PhD | Cleveland Clinic Lerner College of Medicine
    The study by Zeng and colleagues (1) systematically analyzed the survival of patients with seven major types of solid tumors, using a dataset from 1990 to 2009 from the Surveillance, Epidemiology, and End Results (SEER) program by National Cancer Institute (NCI). They argued that younger patients and those diagnosed from 2005-2009 benefited the most from recent advances in cancer treatment. However, one major concern with this study is the underestimation of lead-time bias when reaching the above conclusion. During the past two decades, novel diagnostic test and imaging modality have greatly improved the detection of cancer at early stage. Therefore, a higher proportion of latent and slow-growing tumors would be included in recent time periods such as 2005-2009.Taking prostate cancer as an example, the wide application of prostate specific antigen (PSA) testing since the 1990s has resulted in significant downward stage and grade migration (2,3). Lead-time bias caused by PSA testing is estimated to be as high as 12 years (4), according to the European Randomized Study of Screening for Prostate Cancer (ERSPC). Such change would generate a high risk of overdiagnosis and overtreatment, especially in men who would otherwise have no clinical symptoms during their lifetime. Because survival rate by cancer-specific death was used as the major outcome in this study, the presence of a higher percentage of early stage patients and those with low potential to progress clinically in the cohort of recent time period would confound data interpretation. Although the SEER program has crude information for tumor characteristics (for example, tumor grade and histology were used for adjustment in prostate cancer), these factors might not be sensitive enough to correct for lead-time bias, given the wide range of molecular complexity between tumors of low and high risks. Demographic changes among the 9 SEER registries might further confound the analysis in this study. The authors corrected for SEER registry site, race, sex, and marital status when calculating hazard ratios. However, information such as body mass index or other comorbidities were not collected. Since 1990, the prevalence of overweight and obesity has dramatically increased in the United States (5), and higher BMI is known to be associated with higher cancer incidence especially for breast and colon cancers. Similarly, the evolution of clinical management for other comorbidities linked to cancer, such as diabetes or chronic inflammation, might also contribute to the improved cancer survival seen in this study.

    References:

    1. Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, ZHeng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA Oncology. 2015;1(1):88-96.

    2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270(8):948-954.

    3. Moore AL, Dimitropoulou P, Lane A, et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 2009;104(11):1592-1598.

    4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.

    5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.

    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Investigation
    April 2015

    Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010

    Author Affiliations
    • 1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee
    • 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
    JAMA Oncol. 2015;1(1):88-96. doi:10.1001/jamaoncol.2014.161
    Abstract

    Importance  Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear.

    Objective  To quantify the degree of survival improvement over time by age, race, and sex in the United States.

    Design, Setting, and Participants  Longitudinal analyses of cancer follow-up data from 1990 to 2010, from 1.02 million patients who had been diagnosed as having cancer of the colon or rectum, breast, prostate, lung, liver, pancreas, or ovary from 1990 to 2009 and who were included in 1 of 9 population-based registries of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program.

    Main Outcomes and Measures  Hazard ratios (HRs) and 95% CIs for cancer-specific death were estimated for patients diagnosed as having any of these cancers during 1995 to 1999, 2000 to 2004, and 2005 to 2009, compared with those diagnosed in 1990 to 1994.

    Results  Significant improvements in survival were found for cancers of the colon or rectum, breast, prostate, lung, and liver. Improvements were more pronounced for younger patients. For patients aged 50 to 64 years and diagnosed from 2005 to 2009, adjusted HRs (95% CIs) were 0.57 (95% CI, 0.55-0.60), 0.48 (95% CI, 0.45-0.51), 0.61 (95% CI, 0.57-0.69), and 0.32 (95% CI, 0.30-0.36), for cancer of the colon or rectum, breast, liver, and prostate, respectively, compared with the same age groups of patients diagnosed during 1990 to 1994. However, the corresponding HRs (95% CIs) for elderly patients (those 75-85 years old) were only 0.88 (95% CI, 0.84-0.92), 0.88 (95% CI, 0.82-0.95), 0.76 (95% CI, 0.69-0.84), and 0.65 (95% CI, 0.61-0.70), for the same 4 cancer sites, respectively. A similar, although weaker, age-related period effect was observed for lung and pancreatic cancers. The adjusted HRs (95% CIs) for lung cancer were 0.75 (95% CI, 0.73-0.77) and 0.84 (95% CI, 0.81-0.86), respectively, for patients aged 50 to 64 years and 75 to 85 years diagnosed between 2005 and 2009, compared with the same age groups of patients diagnosed between 1990 and 1994 (0.73 [95% CI, 0.69-0.77] and 0.90 [95% CI, 0.85-0.95], respectively. Compared with whites or Asians, African Americans experienced greater improvement in prostate cancer survival. From 1990 to 2009, ovarian cancer survival declined among African Americans but improved among whites. No apparent sex difference in the degree of improvement for any non–sex-specific cancer was noted.

    Conclusions and Relevance  Younger patients experienced greater benefit from recent oncology advances than elderly patients. African Americans experienced poorer survival than whites for all cancers, and the racial difference decreased for prostate cancer but increased for ovarian cancer. Identifying factors associated with varied improvement in cancer survival can inform future improvements in cancer care for all.

    ×